Compare GLU & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLU | OVID |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.8M | 117.5M |
| IPO Year | N/A | 2017 |
| Metric | GLU | OVID |
|---|---|---|
| Price | $19.91 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 11.1K | ★ 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 8.60% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 0.62 | N/A |
| Revenue | N/A | ★ $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.12 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.07 | $0.24 |
| 52 Week High | $21.69 | $2.38 |
| Indicator | GLU | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 34.50 | 66.01 |
| Support Level | $17.65 | $1.43 |
| Resistance Level | $20.17 | $2.01 |
| Average True Range (ATR) | 0.44 | 0.16 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 4.62 | 58.06 |
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.